A LOOK AT METABOLIC PEPTIDES
CagriSema, retatrutide, cagrilintide, survodutide, zenagamtide and MariTide. See how they differ, what their programmes study and where the clinical science stands.
Educational guide. Treatment choices belong in a conversation with a clinician.
External research catalogues may include materials labelled for laboratory research only. They are not presented here as medicines, personal-use products or approved therapeutic products.
NEW IN THE ATLAS · OCTOBER 2026
What is a peptide? Start with a short animation, then learn to read the evidence behind the headlines.
Educational animation with a synthetic voice. Simplified molecular model.
Hey! I'm Pepi. Peptides are short chains of amino acids. Think of beads linked together. Some carry signals between cells. But a research product is not a medicine! Learn more at Peptide Atlas. Our affiliate links are clearly labelled.
A 3-MINUTE READ
Participants, comparator, duration and safety: six questions to ask before taking a result at face value.
Read the new guideA short chain of amino acids joined by peptide bonds. Read the NHGRI definition ↗
Research involving people that examines a specific question under a predefined plan. Read the new guide →
A document reporting analysis of a material. It is not a clinical trial or a medicine authorisation. How to read a COA →
01 / WHAT’S NEW
New molecules, trial results, regulatory filings and approvals, ordered by publication date and linked to primary sources.
The company reported REIMAGINE 5 and REDEFINE 9 topline results and continued to describe CagriSema as investigational. A reported trial result is not marketing authorisation.
Primary source ↗Lilly announced topline results from TRIUMPH-2 and TRIUMPH-3. Retatrutide remains investigational and is not approved by a regulatory authority.
Primary source ↗The company announced additional Phase 3 CagriSema results and mid-stage data for investigational zenagamtide ahead of ADA 2026.
Primary source ↗Novo Nordisk filed a US application for weight management. A filing is not an approval; CagriSema remains investigational while the review is pending.
Primary source ↗A trial result or regulatory filing is not an approval. We will label an approval only after publication by the relevant regulator.
02 / RESEARCH CATALOGUE
Check the selected batch documentation. CertaPeptides offers 10% with its code; Molequa applies 15% through our affiliate link; Peptides EU gives new customers 10% off their first order through our link.
RESEARCH CATALOGUES
External catalogues for scientific research and development. Check the material, batch record, delivery terms and final checkout information with the merchant.
CERTAPEPTIDES
Public COA vault and batch-specific documentation. For in-vitro research and laboratory use only.
Code at checkout AFF-PEPTIDEATLAS
Explore CertaPeptides Merchant terms apply.PARTICLE PEPTIDES · PARTNER
A public COA Vault searchable by product, batch number and date. Review the documentation before continuing to the catalogue.
MOLEQUA · PARTNER
Public batch documentation and an educational COA checker. Review the exact record and the merchant’s final terms before continuing.
PEPTIDES EU · NEW PARTNER
Peptides and laboratory materials for in-vitro research. Selected Janoshik reports are available on product pages.
Partner links may earn PeptideAtlas a commission at no extra cost to you.
03 / MOLECULES IN FOCUS
These profiles describe molecules in clinical development. Trial data do not establish the quality or safety of products sold by online stores.
GLP-1 + GIP + glucagon
A triple receptor agonist studied in obesity and related conditions. Lilly describes it as an investigational molecule that is not yet approved for use.
GLP-1 + glucagon
A dual receptor agonist studied in overweight and obesity. The clinical programme evaluates both efficacy and safety.
Amylin analogue
A different hormonal approach studied alone and with semaglutide. CagriSema is a separate investigational combination; its results are not results for cagrilintide alone.
Cagrilintide + semaglutide
An investigational fixed-dose combination of cagrilintide and semaglutide. Novo Nordisk reported additional Phase 3 topline results in September 2026; a clinical programme does not amount to marketing authorisation.
GLP-1 + amylin
A unimolecular GLP-1 and amylin receptor agonist. Novo Nordisk describes zenagamtide (amycretin) as an investigational molecule in clinical development, including Phase 3 programmes; it is not an approved medicine.
GLP-1 + GIPR antagonism
An antibody-peptide conjugate studied in the MARITIME programme. Amgen describes MariTide as an investigational molecule in Phase 3; a clinical programme is not regulatory approval.
These profiles are not a ranking and are not a recommendation for use. Regulatory status can change.
04 / CLINICAL DATA IN NUMBERS
These are results from specific trials, doses and time periods. They are not a promise of an individual outcome and do not validate products sold through an online catalogue.
At 48 weeks at the highest studied dose, compared with −2.1% for placebo.
NEJM ↗At 46 weeks at 4.8 mg; the planned-treatment analysis was −14.9% versus −2.8% for placebo.
PubMed ↗REDEFINE 1 reported −20.4% in the treatment-policy analysis; −22.7% was the estimate if all participants adhered to treatment.
Novo Nordisk ↗Different molecules, doses, participants and analyses should not be turned into a simple ranking. Investigational programmes and research-only catalogue products are separate categories.
05 / HOW TO READ THE DATA
Trial results depend on the participants, duration and analysis method. A percentage alone is not enough for a comparison.
Example of regulatory assessment: EMA ↗Check whether participants had diabetes, the inclusion criteria and how long they were followed.
A placebo comparison and a head-to-head medicine trial answer different questions.
Adverse events and treatment discontinuation are part of the assessment. Results do not guarantee an individual effect.
06 / APPROVED MEDICINES
In the EU, specific prescription medicines are approved for weight management. That approval does not transfer to other products with a similar name or composition.
Wegovy — a prescription medicine with weight-management indications for defined patient groups.
Indications and risks at EMA ↗Mounjaro — a prescription medicine with indications that include weight management in defined adult groups.
Indications and risks at EMA ↗These are regulatory examples, not an offer of sale or individual treatment advice. Discuss options with a clinician.
07 / OTHER AREAS
Peptide science includes approved medicines and investigational programmes across many fields. This is a map of research, not a product list.
Insulin, GLP-1 and combination molecules are studied for glucose control, appetite and metabolic risk.
Peptide hormone analogues, including PTH-based therapies, are part of medicine development for bone loss.
Peptide carriers and peptide-drug conjugates are studied to deliver active molecules more precisely.
Peptides and growth factors are investigated for chronic wounds and tissue repair, with different clinical statuses.
Overview of therapeutic areas: PubMed review ↗ EMA links point to approved medicines for defined indications.
09 / FAQ
There is no universal choice. Approved indications, contraindications, other conditions and monitoring matter. A clinician can assess treatment options. Results from different trials are not automatically comparable.
Retatrutide is an investigational molecule in clinical development and is not approved for use. A published trial result is not authorization to sell it as a medicine.
No. Materials labelled for research use are not presented here as medicines or as products for personal use. A certificate of analysis does not turn them into approved medicines.
PeptideAtlas explains the research context and documentation before a visitor follows the clearly marked active catalogue link. The site does not rank products or present research materials as medicines.
There are no registration forms or advertising pixels. We use Umami for aggregate measurement of visits and partner clicks without cookies. External websites have their own policies.